Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Taiho Pharmaceutical

Private
#Oncology#Allergy & Immunology#Urology

R&D-driven Japanese specialty pharmaceutical company and subsidiary of Otsuka Holdings, focused on oncology, allergy and immunology and urology; developer of Lonsurf and futibatinib and parent of Taiho Oncology.

Company Info

Sector:Pharmaceuticals
Headquarters:Chiyoda, Tokyo, Japan
Founded:1963
Website:www.taiho.co.jp/en/

Clinical Development Pipeline

Lonsurf (trifluridine/tipiracil)

Target: Thymidine-based antimetabolite
Metastatic colorectal and gastric cancer
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Futibatinib

Target: FGFR1-4
FGFR2-rearranged intrahepatic cholangiocarcinoma
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Zipalertinib

Target: EGFR exon 20
EGFR exon 20 insertion non-small cell lung cancer
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Masayuki Kobayashi

Representative Director & President

Fabio Benedetti

Global Chief Medical Officer

Utsugi Teruhiro

Executive Director, R&D

Careers & Job Openings

See all open roles

All
Princeton, New Jersey, USA
Apply Now →